Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis.
Elena Nikiphorou, William Tillett, Atul Deodhar et al.
✦ AI-curated · Sources linked
In 30 seconds
This analysis assessed health status, work productivity, and productivity-related costs through 3 years among patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) treated with bimekizumab in phase III trials and open-label extensions. Among 586 patients with axSpA and 1112 with PsA, mean EQ VAS scores improved from baseline by 20.2-21.3 points and 17.1-17.3 points, respectively. Most patients reported clinically meaningful improvement in work impairment at year 3. The authors reported sustained health and work-productivity improvements and estimated US productivity cost savings.
Key findings
- Mean EQ VAS scores improved by 20.2-21.3 points in axSpA and 17.1-17.3 points in PsA from baseline to year 3.
- At year 3, clinically meaningful work-impairment improvement was reported by 74.2-81.1% of patients with axSpA and 71.2-71.3% with PsA.
- At year 3, 83.7-84.2% of patients with axSpA and 84.1-87.2% with PsA had WPAI-SHP presenteeism < 40%.
- Estimated US productivity cost savings sustained to year 3 were $22,012.14-22,549.32 in axSpA and $13,327.60-16,428.25 in PsA.
Why it matters
AxSpA and PsA can affect both perceived health and the ability to work. These findings suggest that improvements in health status and work productivity were maintained during longer-term bimekizumab treatment, with estimated economic savings linked to reduced work impairment. Such outcomes complement clinical measures when considering the broader burden of these chronic inflammatory diseases.
What to keep in mind
The year-3 results are observed-case findings among patients who completed the initial trials and entered open-label extensions; this design may limit generalizability and does not provide a controlled comparison at year 3.